Vanguard Group Inc. Has $72.45 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Vanguard Group Inc. increased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,483,913 shares of the biopharmaceutical company's stock after acquiring an additional 99,730 shares during the quarter. Vanguard Group Inc. owned about 5.40% of Ocular Therapeutix worth $72,453,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in Ocular Therapeutix in the 4th quarter valued at $53,000. Palumbo Wealth Management LLC acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth $100,000. Cibc World Markets Corp bought a new stake in shares of Ocular Therapeutix in the fourth quarter valued at about $124,000. KLP Kapitalforvaltning AS acquired a new position in shares of Ocular Therapeutix in the fourth quarter valued at about $149,000. Finally, Aigen Investment Management LP bought a new position in Ocular Therapeutix during the fourth quarter worth about $159,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Buying and Selling

In other news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Donald Notman sold 11,119 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,895 shares of company stock valued at $283,772 over the last ninety days. 3.50% of the stock is owned by company insiders.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded down $0.33 during mid-day trading on Wednesday, reaching $7.20. The company had a trading volume of 86,645 shares, compared to its average volume of 1,565,888. The business has a fifty day simple moving average of $7.23 and a 200 day simple moving average of $8.56. The company has a market cap of $1.14 billion, a P/E ratio of -5.47 and a beta of 1.49. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. On average, equities research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on OCUL shares. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Ocular Therapeutix has an average rating of "Moderate Buy" and a consensus price target of $16.38.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.